{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:06:36Z","timestamp":1789059996603,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","award":["2008-003396-52"],"award-info":[{"award-number":["2008-003396-52"]}],"id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","award":["NCT00039338"],"award-info":[{"award-number":["NCT00039338"]}],"id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.116984","type":"journal-article","created":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T05:25:20Z","timestamp":1786253120000},"page":"116984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neoadjuvant chemotherapy reduces regulatory T-cells in cervical cancer"],"prefix":"10.1016","volume":"246","author":[{"given":"Jelena M.","family":"Meek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iske F.","family":"van Luijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.J.","family":"Gorris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corneel","family":"Coens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Martynova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"van Ee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena C.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Jolanda M.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma G.","family":"Kenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronella B.","family":"Ottevanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2026.116984_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.ejca.2026.116984_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"10.1016\/j.ejca.2026.116984_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.6004\/jnccn.2019.0001","article-title":"Cervical cancer, version 3.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Koh","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2026.116984_bib4","article-title":"Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994","author":"Kenter","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2026.116984_bib5","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1200\/JCO.2017.75.9985","article-title":"Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial","volume":"36","author":"Gupta","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10460","key":"10.1016\/j.ejca.2026.116984_bib6","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejca.2026.116984_bib7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ijgc-2022-003758","article-title":"Advances in immunotherapy in cervical cancer","volume":"33","author":"Grau","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2026.116984_bib8","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.116984_bib9","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3390\/jcm11092277","article-title":"A Review of the Effects of Cervical Cancer Standard Treatment on Immune Parameters in Peripheral Blood, Tumor Draining Lymph Nodes, and Local Tumor Microenvironment","volume":"11","author":"van Luijk","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2026.116984_bib10","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.2147\/OTT.S264312","article-title":"Cervical Cancer: Emerging Immune Landscape and Treatment","volume":"13","author":"Guo","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.ejca.2026.116984_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1267095","article-title":"Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients","volume":"6","author":"van Meir","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ejca.2026.116984_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death & Differ"},{"issue":"11","key":"10.1016\/j.ejca.2026.116984_bib13","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00262-019-02412-x","article-title":"Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer","volume":"68","author":"Heeren","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.ejca.2026.116984_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13000-018-0770-4","article-title":"Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer","volume":"13","author":"Liang","year":"2018","journal-title":"Diagn Pathol"},{"issue":"11","key":"10.1016\/j.ejca.2026.116984_bib15","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","article-title":"Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics","volume":"20","author":"Hato","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.ejca.2026.116984_bib16","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence","volume":"20","author":"de Biasi","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2026.116984_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cpt.2023.07.003","article-title":"Reversal of the immunosuppressive tumor microenvironment via platinum-based neoadjuvant chemotherapy in cervical cancer","volume":"2","author":"Feng","year":"2024","journal-title":"Cancer Pathog Ther"},{"issue":"8","key":"10.1016\/j.ejca.2026.116984_bib18","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1158\/2326-6066.CIR-19-0616","article-title":"Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4\/IKK2\/SNARE-Dependent Exocytosis","volume":"8","author":"Lau","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2026.116984_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108555","article-title":"The interactions of paclitaxel with tumour microenvironment","volume":"105","author":"Yu","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116984_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(23)00531-4","article-title":"Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116984_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4049\/jimmunol.1701262","article-title":"Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment","volume":"200","author":"Gorris","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2026.116984_bib22","article-title":"A Segmentation-Free Machine Learning Architecture for Immune Land-scape Phenotyping in Solid Tumors by Multichannel Imaging","volume":"2021","author":"Sultan","year":"2021","journal-title":"bioRxiv"},{"issue":"2","key":"10.1016\/j.ejca.2026.116984_bib23","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41416-020-01123-w","article-title":"Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer","volume":"124","author":"Zhang","year":"2021","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116984_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13000-020-00977-1","article-title":"Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy","volume":"15","author":"Liang","year":"2020","journal-title":"Diagn Pathol"},{"issue":"22","key":"10.1016\/j.ejca.2026.116984_bib25","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"10.1016\/j.ejca.2026.116984_bib26","article-title":"Decreasing expression of HIF-1\u03b1, VEGF-A, and Ki67 with efficacy of neoadjuvant therapy in locally advanced cervical cancer","volume":"102","author":"Zhao","year":"2023","journal-title":"Med"},{"issue":"36","key":"10.1016\/j.ejca.2026.116984_bib27","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10421","key":"10.1016\/j.ejca.2026.116984_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2026.116984_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41392-025-02294-9","article-title":"Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3\/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study","volume":"10","author":"Sheng","year":"2025","journal-title":"Signal Transduct Target Ther"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:10:30Z","timestamp":1789056630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":29,"alternative-id":["S0959804926007653"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116984","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant chemotherapy reduces regulatory T-cells in cervical cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116984","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116984"}}